Growth hormone deficiency – childhood onset or adult onset

The PBS subsidises somatropin for patients with childhood onset or adult onset severe growth hormone deficiency.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with somatropin under the National Health Act 1953, section 100 for both:

  • adult patients
  • paediatric patients who have reached mature skeleton.

Where the patient has:

  • adult onset severe growth hormone deficiency, or
  • childhood onset severe growth hormone deficiency.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing somatropin.

Treatment specifics

To be eligible for both initial and continuing PBS subsidised somatropin treatment, patients must be treated by an endocrinologist.

Authority applications to prescribe somatropin are assessed and approved by brand. Prescribers are required to specify the brand on the prescription along with the form and strength.

Authority approvals are valid for the requested brand only and cannot be substituted at the pharmacy. If a patient requires a change in brand part way through the treatment course, a new authority application must be submitted and approved.

Authority Applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS subsidised somatropin for severe growth hormone deficiency can be made either:

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS subsidised somatropin to treat severe growth hormone deficiency can be made either:

Further information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 1 January 2021